文献速递血液净化与透析慢性肾脏病

终末期肾衰竭合并血友病患者接受腹膜透析治疗:病例系列

End Stage Renal Failure Patients With Hemophilia Treated With Peritoneal Dialysis: A Case Series.
PubMed 文献 · Kidney Int Rep · 2022-09-30

单中心回顾性队列纳入1996年1月1日至2021年12月31日北京协和医院8例接受腹膜透析的终末期肾病合并血友病患者,均为男性,平均年龄50.3±13.3岁。7例患者腹膜透析后血红蛋白显著升高,腹膜出血仅占所有出血的一小部分。作者结论认为腹膜透析是安全有效的选择,但需更多研究评估这一罕见人群。

要点

  • 8例终末期肾病合并血友病患者接受腹膜透析,均为男性,平均年龄50.3±13.3岁。
  • 7例患者腹膜透析后血红蛋白显著升高,腹膜出血仅占所有出血的一小部分。
  • 血友病患者小分子溶质清除似乎较低、腹膜炎发生率似乎较高,但本研究把握度不足以证明。

核心结论

  • 腹膜透析是血友病合并终末期肾病需透析患者安全有效的选择。
  • 需要更多研究评估这一罕见患者群体。

研究设计与样本

  • 单中心回顾性队列研究,纳入1996年1月1日至2021年12月31日北京协和医院接受腹膜透析的终末期肾病合并血友病患者,每月随访。
  • 共纳入8例患者,均为男性,平均年龄50.3±13.3岁;其中2例为获得性血友病A,其余为遗传性血友病A。
  • 分析基线临床资料、置管操作、凝血因子替代、并发症及结局,并与一般腹膜透析患者比较。

主要发现

  • 7例患者腹膜透析后血红蛋白显著升高。
  • 腹膜出血仅占所有出血的一小部分。
  • 血友病患者尽管基线腹膜通透性较高,小分子溶质清除似乎较低,且腹膜炎发生率似乎高于其他男性腹膜透析患者,但本研究把握度不足以证明。

临床怎么用

  • 原文结论认为腹膜透析是血友病合并终末期肾病需透析患者安全有效的选择,并指出需更多研究评估该罕见人群。

局限性

  • 本研究为单中心回顾性队列研究。
  • 样本量小(8例),作者指出本研究把握度不足以证明血友病患者小分子溶质清除较低和腹膜炎发生率较高。
  • 作者指出需要更多研究评估这一罕见患者群体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Currently, no consensus on optimal renal replacement modality has been reached for end-stage renal disease (ESRD) patients complicated with hemophilia. They may require infusion of coagulation factors during each hemodialysis session. In comparison, peritoneal dialysis (PD) might be preferred considering that coagulation replacement is only required for catheter placement. However, limited data on the safety and efficacy of PD for treating ESRD patients with hemophilia were reported. METHODS: This is a single-center retrospective cohort study. ESRD patients diagnosed with hemophilia under PD in Peking Union Medical College Hospital from January 1, 1996 to December 31, 2021 were included and followed-up with every month. Their baseline clinical data, catheter insertion procedure, coagulation factor replacement, complications, and outcome were analyzed and compared with general PD patients. RESULTS: In total, 8 patients diagnosed with hemophilia were included, all-male, with a mean age of 50.3±13.3 years old. Two were acquired hemophilia A, whereas the rest were hereditary hemophilia A (HHA). Seven patients experienced significant hemoglobin (Hgb) increment after PD. Peritoneal hemorrhage only consisted of a small portion of all hemorrhage. Patients with hemophilia seemed to have lower small solute clearance despite higher baseline peritoneal permeability, and appeared to have increased peritonitis rate than other male PD patients, yet this study is not powered to prove this. CONCLUSION: PD is a safe and effective choice for patients with hemophilia and ESRD requiring dialysis. More studies are required to evaluate this certain rare group of patients.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Zheng H, Wang H, Zhou Z, et al. End Stage Renal Failure Patients With Hemophilia Treated With Peritoneal Dialysis: A Case Series. Kidney Int Rep. 2022. PMID: 36506225. doi:10.1016/j.ekir.2022.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。